marco.marques – Página 5

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis

marco.marques 2016-07-09T09:20:15+01:00 2013-12-18|Categories: Artrite Psoriática|Tags: methotrexate intolerance, psoriatic arthritis, rheumatoid arthritis|

Maja Bulatović Ćalasan, Oscar FC van den Bosch1 Marjonne CW Creemers, Martijn Custers, Antonius HM Heurkens, Jan Maarten van Woerkom and Nico M Wulffraat Introduction The aim of this study was to determine the prevalence of gastrointestinal and behavioural symptoms occurring before (anticipatory/associative) and after methotrexate (MTX) administration, termed MTX intolerance, in rheumatoid (RA) and psoriatic arthritis (PsA). Methods Methotrexate Intolerance Severity Score [...]

2013 Classification Criteria for Systemic Sclerosis

marco.marques 2016-07-09T08:36:34+01:00 2013-11-1|Categories: Divulgação|

An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative This criteria set has been approved by the American College of Rheumatology (ACR) Board of Directors and the European League Against Rheumatism (EULAR) Executive Committee. This signifies that the criteria set has been quantitatively validated using patient data, and it has undergone validation based on an external data set. [...]

The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

marco.marques 2016-07-09T09:22:29+01:00 2013-9-23|Categories: Artrite Psoriática|

Laura C. Coates, William Tillett, David Chandler, Philip S. Helliwell, Eleanor Korendowych, Stuart Kyle, Iain B. McInnes, Susan Oliver, Anthony Ormerod, Catherine Smith, Deborah Symmons, Nicola Waldron and Neil J. McHugh on behalf of BSR Clinical Affairs Committee & Standards,Audit and Guidelines Working Group and the BHPR Background PsA is a chronic inflammatory arthropathy affecting up to 40% of patients with [...]

What autoantibody tests should become widely available to help scleroderma diagnosis and management?

marco.marques 2016-07-13T08:37:33+01:00 2013-7-19|Categories: Artrite Reumatóide|

Abstract Anti-Th/To autoantibodies have been recognized as serological markers of systemic sclerosis (SSc) for more than 20 years. However, validated immunoassay kits to test this specifi city have not been commercially available. SSc autoantibodies are basically mutually exclusive and are associated with a certain subset of the disease and/or with organ involvement. Anti-Th/ To are generally considered to be markers of the limited cutaneous [...]

Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

marco.marques 2016-10-16T12:02:12+01:00 2013-7-19|Categories: Artrite Reumatóide|Tags: CENP-A, disease activity index, FOXE-3, peptide, Systemic Sclerosis|

Arthritis Research & Therapy 2013, 15:R72 doi:10.1186/ar4249 Federico Perosa (federico.perosa@uniba.it) Elvira Favoino (elvira.favoino@uniba.it) Giovanna Cuomo (Giovanna.CUOMO@unina2.it) Liboria Digiglio (l.digiglio@alice.it) Franco Dammacco (francodam@dimo.uniba.it) Marcella Prete (marcella.prete@uniba.it) Gabriele Valentini (gabriele.valentini@unina2.it) Vito Racanelli (vito.racanelli1@uniba.it) Abstract Introduction: In a subset of patients with limited cutaneous (lc) systemic sclerosis (SSc), antiCENP-A antibodies (Ab) cross-react with a peptide (FOXE3p53-62) that presents striking homology with one of the 2 immunodominant epitopes of [...]

New Rheumatoid Arthritis Guidelines Released

marco.marques 2016-10-16T12:02:12+01:00 2013-7-16|Categories: Artrite Reumatóide|

Medscape Medical News, 2013-06-24 MADRID, Spain — The European League Against Rheumatism (EULAR) guidelines, unveiled here at the 2013 congress, are being updated from 2010 and contain notable differences from the new American College of Rheumatology recommendations. The guidelines, which are not yet published, focus on the efficacy of conventional disease-modifying antirheumatic drugs (DMARDs) as first-line therapy, [...]

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

marco.marques 2016-10-16T12:02:13+01:00 2013-7-12|Categories: Artrite Reumatóide|

James R. O’Dell, M.D., Ted R. Mikuls, M.D., M.S.P.H., Thomas H. Taylor, M.D., Vandana Ahluwalia, M.D., Mary Brophy, M.D., M.P.H., Stuart R. Warren, J.D., Pharm.D., Robert A. Lew, Ph.D., Amy C. Cannella, M.D., Gary Kunkel, M.D., Ciaran S. Phibbs, Ph.D., Aslam H. Anis, Ph.D., Sarah Leatherman, M.A., and Edward Keystone, M.D., for the CSP 551 RACAT Investigators Background Few [...]

Apremilast Eases Psoriatic Arthritis

marco.marques 2016-10-16T12:02:13+01:00 2013-6-13|Categories: Artrite Psoriática|

Published: Jun 13, 2013 | Updated: Jun 14, 2013 By Nancy Walsh, Staff Writer, MedPage Today Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner MADRID -- A year of treatment with apremilast, which targets inflammatory mediators, led to significant long-term reduction in disease activity among [...]

Living with Lupus – Mayo Clinic

marco.marques 2016-10-16T12:02:13+01:00 2013-5-23|Categories: Lúpus Sistémico Eritematoso|

2

Doença de Pompe

marco.marques 2016-10-16T12:02:13+01:00 2013-5-20|Categories: Divulgação|Tags: doença de pompe, pompe|

O que é a Doença de Pompe? A doença de Pompe é uma doença lisossomal de sobrecarga causada pela atividade insuficiente do ácido á-glucosidase.1 Esta enzima lisossómica é responsável pela degradação do glicogénio intralisossómico, o qual representa apenas uma pequena percentagem (1-3%) do glicogénio celular total. A deficiência enzimática resulta numa acumulação de glicogénio lisossomal em múltiplas [...]

Núcleo de Estudos de Doenças Auto-imunes

About marco.marques